

Whole-Body Hypothermia for Neonatal Encephalopathy in Preterm Infants 33 to 35 Weeks' Gestation

A Randomized Clinical Trial

Roger G. Faix, MD; Abbot R. Laptook, MD; Seetha Shankaran, MD; Barry Eggleston, MS; Dhuly Chowdhury, MS, MBA; Roy J. Heyne, MD; Abhik Das, PhD; Claudia Pedroza, PhD; Jon E. Tyson, MD, MPH; Courtney Wusthoff, MD, MS; Sonia L. Bonifacio, MD; Pablo J. Sánchez, MD; Bradley A. Yoder, MD; Matthew M. Laughon, MD, MPH; Diana M. Vasil, MSN, BSN, RNC-NIC; Krisa P. Van Meurs, MD; Margaret M. Crawford, BS, CCRP; Rosemary D. Higgins, MD; Brenda B. Poindexter, MD, MS; Tarah T. Colaizy, MD, MPH; Shannon E. G. Hamrick, MD; Lina F. Chalak, MD, MSCS; Robin K. Ohls, MD; Michele E. Hartley-McAndrew, MD; Kevin Dysart, MD; Carl T. D'Angio, MD; Ronnie Guillet, MD, PhD; Stephen D. Kicklighter, MD; Waldemar A. Carlo, MD; Gregory M. Sokol, MD; Sara B. DeMauro, MD, MSCE; Anna Maria Hibbs, MD, MSCE; C. Michael Cotten, MD, MHS; Stephanie L. Merhar, MD, MS; Roopali V. Bapat, MD, MSHQS; Heidi M. Harmon, MD, MS; Elizabeth Sewell, MD; Sarah Winter, MD; Girija Natarajan, MD; Ricardo Mosquera, MD, MS; Susan R. Hintz, MD, MSEpi; Nathalie L. Maitre, MD, PhD; Kristen L. Benninger, MD, MSc; Myriam Peralta-Carcelen, MD, MPH; Abbey C. Hines, PsyD; Andrea F. Duncan, MD, MSClinRes; Deanne E. Wilson-Costello, MD; Andrea Trembath, MD, MPH; William F. Malcolm, MD; Michele C. Walsh, MD, MS; for the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network

IMPORTANCE Hypothermia begun less than 6 hours after birth reduces death or disability in infants with encephalopathy due to hypoxia-ischemia at 36 or more weeks' gestation. Trials of hypothermia for infants younger than 36 weeks' gestation are lacking.

OBJECTIVE To assess the probability that hypothermia at less than 6 hours after birth decreases death or disability in infants 33 to 35 weeks' gestation with moderate or severe hypoxic-ischemic encephalopathy.

DESIGN, SETTING, AND PARTICIPANTS This randomized clinical trial was conducted between July 2015 and December 2022 for infants 33 to 35 weeks' gestation with moderate or severe hypoxic-ischemic encephalopathy at less than 6 hours after birth. Bayesian and intention-to-treat analyses were prespecified. The setting included 19 US Neonatal Research Network centers. Data were analyzed from March 2023 to November 2024.

INTERVENTIONS Infants received unblinded targeted esophageal temperature management. Infants with hypothermia were maintained at 33.5 °C (acceptable 33-34 °C) for 72 hours and then rewarmed. Infants with normothermia were to be maintained at 37 °C (acceptable 36.5-37.3 °C).

MAIN OUTCOMES AND MEASURES Composite of death or disability (moderate or severe) at 18 to 22 months' corrected age adjusted for level of encephalopathy and center.

RESULTS A total of 168 infants with hypothermia and normothermia were preterm (mean [SD] age, 34.0 [0.8] weeks' gestation and 34.1 [0.8] weeks' gestation, respectively), while 46 of 88 (52%) and 45 of 80 (56%) were male, respectively. Randomization occurred at mean (SD) 4.5 (1.2) hours and 4.5 (1.3) hours for the groups with hypothermia and normothermia, respectively. The primary outcome occurred in 29 of 83 infants (35%) with hypothermia and 20 of 69 infants (29%) with normothermia (adjusted relative risk [hypothermic/normothermic], 1.11; 95% credibility interval, 0.74-2.00), and death occurred in 18 of 88 infants (20%) with hypothermia and 9 of 78 infants (12%) with normothermia (adjusted relative risk, 1.38; 95% credibility interval, 0.79-2.85). Bayesian analysis with neutral prior indicated 74% probability of increased death or disability and 87% probability of increased death with hypothermia.

CONCLUSIONS AND RELEVANCE Among infants 33 to 35 weeks' gestation with hypoxic-ischemic encephalopathy, hypothermia at less than 6 hours' age did not reduce death or disability at 18 to 22 months' corrected age.

TRIAL REGISTRATION ClinicalTrials.gov Identifier: [NCT01793129](https://clinicaltrials.gov/ct2/show/study/NCT01793129)

JAMA Pediatr. 2025;179(4):396-406. doi:10.1001/jamapediatrics.2024.6613
Published online February 24, 2025.

[+ Visual Abstract](#)

[+ Supplemental content](#)

Author Affiliations: Author affiliations are listed at the end of this article.

Group Information: The members of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network appear in Supplement 4.

Corresponding Author: Roger G. Faix, MD, Division of Neonatology, Department of Pediatrics, University of Utah Health Sciences Center, University of Utah, 295 Chipeta Way, Salt Lake City, UT 84108 (roger.faix@hsc.utah.edu).

Perinatal hypoxia-ischemia (HI) is a major cause of brain injury and death at all gestational ages (GAs). The only effective treatment supported by multiple randomized clinical trials (RCTs) is therapeutic hypothermia for infants 36 weeks' GA and older.¹⁻⁵ Despite minimal evidence for efficacy and safety at less than 36 weeks, use of hypothermia in such infants has increased.^{6,7} Multiple reports describe such experience without randomized controls.⁸⁻¹¹ Infants with GA younger than 36 weeks may be at increased risk for problems that may be triggered or respond adversely to therapeutic hypothermia (eg, intracranial hemorrhage, necrotizing enterocolitis, coagulopathy, shock) as well as death.

We conducted a randomized clinical trial to assess effectiveness and safety of therapeutic hypothermia in infants 33 to 35 weeks' GA. We hypothesized that therapeutic hypothermia (esophageal temperature [Tes] 33.5 °C) for 72 hours will decrease death or moderate/severe disability at 18 to 22 months' corrected age in infants with moderate or severe encephalopathy due to HI at less than 6 hours of age compared with infants treated with targeted normothermia (Tes, 37.0 °C)

Methods

Ethics Approval

Study documents and consent forms were reviewed and approved by the institutional review boards at all participating institutions. Written informed consent by a parent or legal guardian was required. The trial protocol and statistical analysis plan are available in [Supplement 1](#) and [Supplement 2](#), respectively. This study followed the Consolidated Standards of Reporting Trials (CONSORT) reporting guidelines.

Inclusion and Exclusion Criteria

Many features of this trial were similar to previous therapeutic hypothermia trials conducted by the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network (NRN).^{2,12,13} All infants admitted to neonatal intensive care units (NICUs) of participating centers at 33-0/7 to 35-6/7 weeks' GA by best obstetrical estimate and less than 6 hours of age with a diagnosis of encephalopathy, perinatal asphyxia, neurologic depression, or similar condition were screened for eligibility. Inclusion criteria required both (1) blood pH (cord or neonatal at <1 hour) of 7.0 or less or base deficit greater than or equal to 16 mEq/L or, if no blood gas or lesser acidosis (pH 7.01-7.15 or base deficit 10.0-15.9 mEq/L), an acute perinatal event with either 10-minute Apgar score of 5 or less or ventilation initiated at birth and continued for 10 minutes or longer and (2) moderate or severe encephalopathy using modified Sarnat score assessed by certified examiners or clinical seizures at less than 6 hours.^{2,12,13} Clinical seizures did not require electroencephalography confirmation. Because of concern about changes in Sarnat scoring attributable to prematurity, abnormal level of consciousness (moderate or severe) was required to be present. Similarly, criteria for posture and Moro reflex were modified to account for maturational changes between 33 and 35 weeks' GA.¹⁴ Exclusion criteria included the following: (1) core

Key Points

Question Does hypothermia initiated at less than 6 hours after birth reduce the probability of death or disability at 18 to 22 months' corrected age in infants 33 to 35 weeks' gestation with neonatal encephalopathy due to hypoxia-ischemia?

Findings In this bayesian randomized clinical trial of 168 newborns of 33 to 35 weeks' gestation with hypoxic-ischemic encephalopathy, treatment with hypothermia resulted in a 74% probability of increased death or disability and 87% probability of increased death at 18 to 22 months' corrected age.

Meaning This trial provided no evidence that hypothermia begun at less than 6 hours after birth in infants 33 to 35 weeks' gestation with hypoxic-ischemic encephalopathy decreases death or disability at 18 to 22 months' corrected age.

temperature less than 34.0 °C for greater than 1 hour before screening, (2) receipt of paralytic or sedative agents obscuring Sarnat examination, (3) encephalopathy unlikely due to HI, (4) major anomaly, (5) moribund and not receiving intensive care, (6) birth weight less than 1500 g, and (7) clinician-declined enrollment. Thermal management before randomization was per practice at each center. Passive cooling (ie, withholding external heat) during transport was discouraged. Randomization was performed by telephone with the Research Triangle Institute data center using computer-generated randomized permuted block algorithm with block sizes 2 and 4 in 1:1 ratio and stratified for encephalopathy level (moderate vs severe) and center. Participants belonged to the following parent- or guardian-identified races and ethnicities: Black, Hispanic, White, and other, which included Asian, Native American, Pacific Islander, and unspecified. Race and ethnicity were reported as required for clinical studies funded by the National Institutes of Health.

Materials and Measures

After randomization, all infants underwent placement of a temperature monitoring probe in the distal esophagus. Placement time was considered time 0. By 108 hours, esophageal probes were removed and further thermal management implemented per local practice.

Those randomized to hypothermia underwent whole-body cooling with a Blanketrol Hyper-Hypothermia II or III device (Cincinnati Subzero). This device was used with an US Food and Drug Administration investigational device exemption because of the study population GA. Target Tes was 33.5 °C (range, 33.0-34.0 °C) for 72 hours. Rapid cooling with this device is accompanied by a transient Tes decrease below the target (overshoot) followed by warming to return to target, then maintained. Overshoot occurs most often with cooling initiation. Tes in this group was recorded every 15 minutes for the first 4 hours, every hour for the next 8 hours, and every 2 hours for the remaining intervention period. Rewarming proceeded at 0.5 °C per hour.

Those randomized to normothermia had a target Tes of 37.0 °C. Temperature monitoring was similar except for hourly temperatures during the first 4 hours. Skin temperature associated with Tes 37.0 °C for individual infants was identified

and servo-controlled by radiant warmer or incubator to maintain T_{es} 36.5 to 37.3 °C. Because of the association of hyperthermia with adverse outcomes, steps were incorporated to minimize hyperthermia in this group.¹⁵⁻¹⁷ If T_{es} greater than 37.3 °C occurred, standard thermoregulatory management was verified. If T_{es} was greater than 37.5 °C, a single tepid sponge bath was implemented, and if unsuccessful, active cooling with the Cincinnati Subzero cooling blanket was implemented until the target T_{es} was attained.

Cranial ultrasound was required within 24 hours of randomization, and brain magnetic resonance imaging (MRI) was required at 7 to 21 days postnatal age in survivors. MRI results will be reported separately. Laboratory and imaging studies were obtained per standard care. Infants were not fed during the intervention. Other aspects of management such as sedation/analgesia, respiratory support, and anticonvulsant therapy were managed by local standards.

Primary Outcome

The primary outcome was death or disability (severe or moderate) at 18 to 22 months' corrected age. Certified examiners trained to reliability perform assessments at follow-up were blinded to group assignment, including postdischarge history, growth, neurologic examination, Bayley Scales of Infant Development third edition (Bayley III), Gross Motor Function Classification System level (GMFCS), and vision and hearing status. Severe disability was deemed present by any of the following: Bayley III cognitive score less than 70, GMFCS level 3 to 5, blindness, or hearing loss with inability to hear commands despite amplification. Moderate disability was defined by a cognitive score of 70 to 84 and any of GMFCS level 2, treated seizure disorder, or hearing loss requiring amplification or implant to understand commands. Infants with cognitive score greater than or equal to 85 and no deficits were considered normal.

Secondary Outcomes

Prespecified secondary outcomes included death alone, severe or moderate disability only, death or profound disability (defined as severe disability with assignment of lowest possible cognitive score because infant untestable due to impairment), survival with normal outcome, each component of severe and moderate disability, and cause of death.

Safety

Adverse events included arrhythmia requiring treatment, persistent metabolic acidosis, thrombosis, bleeding, altered skin integrity, and death as in prior NRN hypothermia trials.^{2,12,13} Additionally, intracranial hemorrhage, seizures after randomization, necrotizing enterocolitis of Bell stage greater than or equal to II,¹⁸ spontaneous intestinal perforation, major bleeding (prompting blood product administration), thrombocytopenia ($<100,000/\text{mm}^3$), hypoglycemia ($<30 \text{ mg/dL}$), hyperglycemia ($>180 \text{ mg/dL}$), bronchopulmonary dysplasia, pulmonary hypertension, late-onset culture-proven bloodstream infection, esophageal probe injuries, receipt of extracorporeal membrane oxygenation, abnormalities of electrolytes, calcium, phosphorus, or magnesium, and other morbidities were pro-


spectively tracked. The NRN data safety monitoring committee (DSMC) reviewed cumulative outcomes and adverse events at 6 specified intervals during the trial: after 20, 40, 60, 80, 100, and 130 infants reached NICU discharge, were alive in the NICU at 60 days, or had died by 60 days.

After its third review of cumulative data on September 17, 2017, the DSMC requested additional measures to prevent or correct T_{es} less than 32 °C. The following steps were implemented: (1) change precooling blanket before intervention from 5 to 15 °C, (2) immediate notification of research staff if T_{es} less than 32.0 °C, (3) T_{es} recorded every 10 minutes until target T_{es} attained, and (4) documentation of corrective actions.

Statistical Analysis

Intention-to-treat analyses were prespecified. Using retrospective review of NICU admission records at participating centers in 2012, the number of eligible infants for a 5-year period was estimated to approach 170. Simulations showed that the trial design had greater than 75% chance of observing final posterior probability of less than or equal to 0.80 for relative risk less than 1, when true relative risk is near 0.70. The trial was designed using bayesian principles to assess primary and other outcomes. The bayesian approach assesses probability of treatment benefit/harm based on observed data and allows for formal inclusion of any prior data.^{19,20} Binary outcomes were modeled using logistic regression, and predicted outcome probabilities were postprocessed using the method of Gelman to estimate posterior distribution of relative risk and risk difference (RD).²¹ Models were adjusted for level of encephalopathy and center as random effects. Posterior distributions of adjusted risk ratio (aRR) and adjusted RD (aRD) were used to estimate 95% credibility intervals (CrIs) and posterior probabilities of benefit/harm for outcomes. aRR was determined using hypothermia group results as numerator and normothermia as denominator, and aRD was determined by subtracting normothermia results from those of the hypothermia group. Neutral prior for aRR (centered on 1.0, with 50% prior probability of better outcome and 50% of worse outcome) was preselected given no preexisting trials for this intervention in the target GA range. Prespecified assessments of enthusiastic (centered on aRR 0.75) and skeptical (centered on aRR 1.1) prior probabilities were also conducted. These priors and CrIs were based on largest effect sizes identified for major outcomes in randomized trials and exclude implausible effect sizes.²² For death or severe disability and other binary outcomes, the 3 priors were centered at -0.29, 0, and 0.10, respectively, on the log odds ratio (OR) scale, with 95% CrIs on that scale of -1.39 to 1.39 for neutral, -1.67 to 1.10 for enthusiastic, and -1.29 to 1.48 for skeptical. To produce neutral prior for aRR within a linear regression model, a normal prior with mean 0 and SD 0.71 was placed on the treatment parameter in the logistic regression. Probability of treatment benefit and harm was assessed by determining areas under the posterior probability distribution curve with aRR less than 1.0 and greater than 1.0. All analyses were conducted in SAS, version 9.4 (SAS Institute), or R, version 4.2.2 (R Project for Statistical Computing), and all models were assessed for convergence using visual observation of trace plots within SAS and Gelman-

Figure 1. Consolidated Standards of Reporting Trials (CONSORT) Flow Diagram



Rubin statistics based on 3 Markov chain Monte Carlo chains. Data were analyzed from March 2023 to November 2024.

Results

From July 2015 to September 2020, 168 infants were randomized (Figure 1), 88 to the hypothermia cohort (mean [SD] age, 34.0 [0.8] weeks' gestation; 42 female [48%]; 46 male [52%]) and 80 to the normothermia cohort (mean [SD] age, 34.1 [0.8] weeks' gestation; 35 female [44%]; 45 male [56%]). Infants in the hypothermic cohort were parent or guardian identified as the following races and ethnicities: 27 Black (31%), 15 Hispanic (17%), 52 White (59%), and 9 other (10%). Infants in the normothermic cohort were parent or guardian identified as the following races and ethnicities: 31 Black (39%), 10 Hispanic (12%), 42 White (52%), and 7 other (9%). No participant qualified by clinical seizures alone. One infant randomized to hypothermia did not receive that intervention due to late discovery of temperature less than 34 °C for more than 1 hour before screening but was analyzed as receiving hypothermia per intention to treat. Of those randomized to normother-

mia, 2 were withdrawn by parents immediately after randomization but before intervention and were not analyzed beyond features present at randomization.

Demographic and clinical characteristics of mother and infant before randomization were similar between the groups (Table 1). Mean (SD) *T*_{es} of the 2 groups during the intervention demonstrated expected differences (hypothermia, 33.4 [0.2] °C vs normothermia, 37.2 [0.2] °C) (eFigure in the Supplement 3). In the normothermia group, 16 infants met the threshold for treatment of *T*_{es} greater than 37.5 °C.

The last patient completed follow-up in December 2022. Follow-up intended for 18 to 22 months was delayed in 52 infants due to the COVID-19 pandemic-related restrictions. In those cases, data from the earliest delayed follow-up visit were used; mean (SD) corrected age for these infants was 26 (4) months (range, 23-40 months). One infant whose age exceeded Bayley III examination limit was considered lost to follow-up.

Randomization occurred at mean (SD) 4.5 (1.2) hours and 4.5 (1.3) hours for the groups with hypothermia and normothermia, respectively. The primary outcome of death or moderate/severe disability occurred in 29 of 83 infants (35%)

Table 1. Maternal and Neonatal Characteristics at Randomization

Maternal	No./total No. (%)	
	Infant	
	Hypothermic (n = 88)	Normothermic (n = 80)
Age, mean (SD), y	30.9 (6.1)	28.8 (6.4)
Married	43/88 (49)	47/80 (59)
Race ^a		
Black	27/88 (31)	31/80 (39)
White	52/88 (59)	42/80 (52)
Other ^b	9/88 (10)	7/80 (9)
Ethnicity		
Hispanic ^a	15/88 (17)	10/80 (12)
Gravida, median (IQR), No. of pregnancies	3 (2-5)	2 (2-4)
No.	87	80
Parity, median (IQR), No. of births	2 (1-3)	2 (1-3)
No.	87	80
Education		
High school or less	20/83 (24)	22/73 (30)
Any college or more	63/83 (76)	51/73 (70)
Pregnancy complications		
Preeclampsia/hypertension	32/87 (37)	31/78 (40)
Antepartum hemorrhage	25/87 (29)	21/79 (27)
Thyroid dysfunction	4/87 (5)	8/77 (10)
Diabetes	21/88 (24)	22/77 (29)
Intrapartum complications		
Fetal decelerations	69/87 (79)	57/79 (72)
Cord mishap	9/86 (10)	7/78 (9)
Uterine rupture	6/86 (7)	1/78 (1)
Maternal fever (temperature, 37.6 °C)	2/84 (2)	3/75 (4)
Placental problem (any)	38/86 (44)	36/78 (46)
Abruptio	35/86 (41)	36/78 (46)
Previa	1/86 (1)	0/78 (0)
Accreta	1/86 (1)	0/78 (0)
Maternal trauma	1/86 (1)	5/79 (6)
Maternal hemorrhage	17/85 (20)	16/78 (20)
Shoulder dystocia	3/86 (4)	3/78 (4)
Rupture of membranes, yes	36/81 (44)	20/75 (27)
Duration, median (IQR), h before delivery	4.2 (0.3-27.6)	1.5 (0.1-13.3)
No.	32	19
≤18 h	22/32 (69)	16/19 (84)
>18 h	10/32 (31)	3/19 (16)
Histologic chorioamnionitis	11/59 (19)	7/45 (16)
Emergent cesarean delivery	68/88 (77)	67/80 (84)
Infant		
Gestational age, mean (SD), wk	34.0 (0.8)	34.1 (0.8)
Birth weight, mean (SD), g	2464 (634)	2371 (608)
Length, mean (SD), cm	46.0 (3.2)	45.1 (2.8)
No.	86	76
Head circumference, mean (SD), cm	32.0 (1.8)	31.7 (1.8)
No.	86	77
Male	46/88 (52)	45/80 (56)
Outborn	47/88 (53)	47/80 (59)

(continued)

Table 1. Maternal and Neonatal Characteristics at Randomization (continued)

Maternal	No./total No. (%)	
	Infant	
	Hypothermic (n = 88)	Normothermic (n = 80)
Delivery room resuscitation		
Intubation	56/88 (64)	50/79 (63)
Chest compressions	40/88 (46)	30/79 (38)
Epinephrine	26/88 (30)	26/79 (33)
Time to spontaneous breaths, median (IQR), min	2.0 (1.0-3.0)	2.0 (1.0-3.0)
No.	80	74
Apgar score <5		
At 5 min	54/86 (63)	48/79 (61)
At 10 min	36/70 (51)	29/67 (43)
Cord blood or if unavailable, neonatal blood gas at <1 h postnatal age		
Mean (SD), pH	6.9 (0.2)	6.9 (0.2)
No.	69	68
Mean (SD), base deficit	17.7 (7.0)	17.0 (7.7)
No.	60	59
Age at randomization, mean (SD), h	4.5 (1.2)	4.5 (1.3)
Level of encephalopathy		
Moderate	61/88 (69)	57/80 (71)
Severe	27/88 (31)	23/80 (29)
Clinical seizures at randomization	14/88 (16)	11/80 (14)

^a Race and ethnic group were reported by parent or guardian.^b Other race includes Asian, Native American, Pacific Islander, and unspecified.

randomized to hypothermia vs 20 of 69 infants (29.0%) randomized to normothermia (Table 2). aRR using neutral prior probability was 1.11 (95% CrI, 0.74-2.00), yielding probability of benefit, 26%, and of harm, 74% (Figure 2). eTable 1 in Supplement 3 presents analyses using skeptical and enthusiastic priors. Death occurred in 18 of 88 infants (20%) with hypothermia and 9 of 78 infants (12%) with normothermia (aRR for death alone, 1.38; 95% CrI, 0.79-2.85) with probability of benefit, 13%, and of harm, 87%. Assessment for treatment heterogeneity with hypothermia revealed benefit probability 38% for males and 25% for females, and this probability was 35% for White infants and 11% for Black infants. Stratification by GA in exploratory analysis revealed higher incidence of primary outcome in hypothermic infants at each GA and of death at each GA except 33 weeks (eTable 2 in Supplement 3).

In exploratory analysis, it was noted that 32 infants randomized to hypothermia and 1 to normothermia attained Tes less than 32 °C during the intervention (with duration <1 hour in 26). Exclusion of all such infants (eTable 3 in Supplement 3) revealed no clinically important difference between groups for the primary outcome or death alone.

Death was attributed by site investigators to asphyxial brain injury in 15 of 18 infants (83%) in the hypothermia cohort and 5 of 9 infants (56%) in the normothermia cohort. Multiorgan failure was considered cause of death in 2 of 18 infants (11%) in the hypothermia cohort and 2 of 9 infants (22%) in the normothermia cohort. Cause of death in 2 remaining infants in the normothermia cohort were pulmonary hypoplasia with chronic

Table 2. Comparison of Primary and Secondary Outcomes in Infants Using Neutral Prior^a

Outcome	Group, No./total No. (%)		Bayesian effect	Median (95% CrI) ^{c,d}	Posterior probability of benefit, % ^e
	Hypothermia (n = 88)	Normothermia (n = 78) ^b			
Primary outcome					
Death or moderate or severe disability	29/83 (35)	20/69 (29)	aRD	0.04 (−0.08 to 0.18)	26
			aRR	1.11 (0.74 to 2.00)	26
Secondary outcomes ^f					
Any death	18/83 (22)	9/69 (13)	aRD	0.05 (−0.05 to 0.26)	13
			aRR	1.38 (0.79 to 2.85)	13
Survival with moderate or severe disability	11/83 (13)	11/69 (16)	aRD	−0.02 (−0.15 to 0.09)	68
			aRR	0.86 (0.46 to 1.63)	68
Death or severe disability	27/83 (32)	20/69 (29)	aRD	0.02 (−0.11 to 0.15)	38
			aRR	1.05 (0.67 to 1.82)	38
Death or moderate or severe disability with initial moderate NE	9/56 (16)	6/48 (12)	aRD	0.03 (−0.09 to 0.14)	32
			aRR	1.18 (0.59 to 2.41)	32
Death or moderate or severe disability with initial severe NE	20/27 (74)	14/21 (67)	aRD	0.06 (−0.14 to 0.26)	28
			aRR	1.09 (0.81 to 1.53)	28
Cause of death: asphyxial brain injury	15/18 (83)	5/9 (56)	aRD	0.10 (−0.13 to 0.36)	18
			aRR	1.17 (0.80 to 2.19)	18
Cause of death: multiorgan failure	2/18 (11)	2/9 (22)	aRD	−0.04 (−0.27 to 0.15)	69
			aRR	0.8 (0.32 to 2.04)	69
Clinical seizures after randomization	13/86 (15)	11/75 (15)	aRD	0.0 (−0.12 to 0.13)	47
			aRR	1.02 (0.55 to 1.92)	47

Abbreviations: aRD, adjusted risk difference; aRR, adjusted risk ratio; NE, neonatal encephalopathy; Pr, posterior probability.

^a Models adjusted for level of encephalopathy and included center as a random effect.

^b Excluded 2 withdrawn infants.

^c Posterior median of probability distribution.

^d Posterior 95% credible interval.

^e Posterior probability of benefit due to whole body hypothermia. For relative risk, this is $\text{Pr}(\text{relative risk} < 1 \mid \text{trial data})$, and for risk difference this is $\text{Pr}(\text{RD} < 0 \mid \text{trial data})$. For relative risk, the comparison is whole body hypothermia over normothermia; therefore, relative risk values less than 1 indicate benefit for whole body hypothermia. For risk difference, the comparison is whole body hypothermia minus normothermia; therefore, risk difference values less than 0 indicate benefit for whole body hypothermia.

^f Although profound disability was prespecified as a secondary outcome of interest, only 1 infant (normothermic) met criteria and results are therefore not included in the table.

pulmonary hypertension and severe bronchopulmonary dysplasia, whereas cause in the remaining infant in the hypothermia cohort was cardiomyopathy. All but 2 deaths followed decisions to redirect care or forego resuscitation. Three deaths (2 hypothermia, 1 normothermia) occurred after NICU discharge, including 1 discharged on hospice care. Bayesian analysis with neutral prior indicated 74% probability of increased death or disability and 87% probability of increased death with hypothermia.

The frequency of prespecified nondeath safety events during intervention was generally comparable in the 2 groups (Table 3). The posterior probability that hypothermia was beneficial in reducing these events ranged from 25 to 81%, except for hyperglycemia (5%), hyponatremia (1%), days on mechanical ventilation (1%), and hypoglycemia (87%). Details of intracranial hemorrhage on ultrasound before, during, and after the intervention during NICU course are in eTable 4 in Supplement 3. Two normothermic infants had intestinal perforation after intervention, 1 due to spontaneous intestinal perforation and 1 due to previously undiagnosed ileal atresia.

Discussion


Our findings indicate that therapeutic hypothermia initiated by 6 hours postnatal age did not reduce the primary outcome of death or moderate/severe disability or death alone at 18 or more months in infants born at 33 to 35 weeks' GA with moderate or severe neonatal encephalopathy. A 74% probability of treatment harm for the primary outcome and 87% for death alone with hypothermia was observed. Other prespecified

safety events were generally comparable between groups. Although survival with moderate or severe disability appeared to be slightly better in the hypothermic group, the absolute difference was small (13 vs 16%), and this potential small benefit was accompanied by a much higher incidence of death.

Most studies demonstrating effectiveness of hypothermia for neonatal encephalopathy limited their population to 36 weeks' GA or older.^{1–5} Two RCTs with follow-up at 12 to 24 months included enrollment at 35 weeks, but the publications did not specify how many such infants were included nor their outcomes.^{23–25} The American Academy of Pediatrics Committee of Fetus and Newborn considered 1 of those trials in their 2014 recommendation for hypothermia in infants 35 weeks' GA and older.²⁶ Personal communication in 2014 with the authors of those 2 RCTs revealed the total number of 35 weeks' GA infants in those studies to be 7, with 2 randomized to control (1 death, 1 normal survivor) and 5 to cooling (2 deaths, 2 survivors with moderate disability, 1 normal survivor). Unlike those 2 trials, our trial required abnormal level of consciousness and may select sicker patients. Our findings for 48 infants born at 35 weeks' GA provide no support for hypothermia at that GA.

Reasons for absent benefit with hypothermia among preterm infants in our trial are unclear and may be multifactorial. First, developmental differences may alter risk-benefit balance with hypothermia compared with infants 36 weeks' GA or older. Second, antepartum environment and perinatal events may differ between preterm and term infants. Rates of placental abruption were more than 3-fold higher in the present study than in the nEuro trial (11.6% with placental problems, including abruption) and Late Hypothermia trial (11.3%).^{5,12}

Figure 2. Posterior Probability of Relative Risk for Primary Outcome



Maternal hypertensive disorders were 2-fold higher than in the Late Hypothermia trial (17.8%).¹² Finally, protocol-directed correction of hyperthermia in the normothermic group may have altered outcomes. Noncooled comparison groups from prior RCTs that experienced higher core temperatures were associated with increased risk of death or moderate/severe disability.¹⁵⁻¹⁷ The effect of measures to avoid high Tes in our normothermic infants is unclear.

The observation that many infants randomized to hypothermia attained Tes less than 32.0 °C. during the intervention is not surprising since preterm infants in general are known to have limited thermoregulatory ability. It is unclear if increased frequency of primary outcome and death alone seen in those infants reflects a direct effect of overshoot or if overshoot is simply a marker for infants who had sustained more severe hypoxic-ischemic insult and were at higher risk for adverse outcomes. Newer generations of whole-body cooling devices are reported by manufacturers to have reduced likelihood of overshoot but it is unknown if that will yield any meaningful difference in outcomes. It is noteworthy in our study that if all infants with Tes less than 32.0 °C. are excluded, there was still no notable benefit with hypothermia.

Prospective estimates of the incidence of neonatal encephalopathy among infants 33 to 35 weeks' GA are lacking. A single-center retrospective review of such infants who fulfilled inclusion criteria for a prior hypothermia trial estimated an incidence of 5 per 1000 live births.²⁷ Studies of neonatal encephalopathy at 33 to 35 weeks' GA will thus have limited sample size given the small number of births at these GAs compared with trials enrolling infants 36 weeks' GA and older even with multiple, large referral centers. Frequentist analysis with typical assumptions of types I and II error and outcome difference require a larger number of subjects than this multi-site study could accrue over 5 years. Bayesian analysis is particularly recommended for uncommon conditions to provide an estimate of the probability of benefit or harm due to an intervention based on trial results combined with preexisting data.^{19,20} Estimating the probability of benefit or harm may yield meaningful information to clinicians, patients, and family.

Strengths and Limitations

This study offers significant information that may strongly influence clinical practice. It offers strengths of being a

Table 3. Neonatal Safety Events During Intervention Period (Relative Risk: Hypothermic/Normothermic Groups)

Adverse event during intervention	No./total No. (%)		Posterior probability of benefit, %	Posterior aRR (95% CrI)
	Hypothermic (n = 88)	Normothermic (n = 78)		
Arrhythmia needing treatment	1/88 (1.1)	1/78 (1.3)	54	0.95 (0.33-2.73)
Persistent metabolic acidosis ^a	4/88 (4.5)	5/78 (6.4)	65	0.84 (0.35-1.99)
Thrombosis	0/88 (0)	0/78 (0)	Cannot be estimated	Cannot be estimated
Intracranial bleeding ^b	6/88 (8)	5/78 (8)	53	1.03 (0.46-2.33)
Major bleeding	1/88 (1.1)	4/78 (5.1)	81	0.65 (0.24-1.69)
Thrombocytopenia	11/88 (12.5)	12/78 (15.4)	67	0.87 (0.44-1.67)
Treatment with vasopressors	28/88 (32)	23/78 (30)	43	1.03 (0.65-1.71)
Treatment with steroids	9/75 (12)	7/70 (10)	38	1.12 (0.54-2.38)
Oliguria/anuria ^c	6/85 (7)	3/74 (4)	30	1.24 (0.53-2.98)
Liver dysfunction ^d	40/88 (46)	38/78 (49)	68	0.94 (0.67-1.26)
Serum sodium <120 mEq/L	8/88 (9)	0/78 (0)	4	2.25 (0.94-5.90)
Serum sodium >150 mEq/L	5/88 (6)	1/78 (1)	20	1.51 (0.59-3.92)
Serum potassium <3.0 mEq/L	21/88 (24)	22/78 (28)	72	0.87 (0.55-1.38)
Serum potassium >6.0 mEq/L	16/88 (18)	19/78 (24)	80	0.80 (0.47-1.34)
Serum calcium <7.0 mg/L	29/82 (35)	26/71 (37)	57	0.97 (0.66-1.43)
PPHN	5/88 (5.7)	4/78 (5.1)	48	1.03 (0.43-2.48)
Hyperglycemia	20/88 (22.7)	9/78 (11.5)	5	1.64 (0.92-3.27)
Hypoglycemia	1/88 (1.1)	5/78 (6.4)	87	0.58 (0.22-1.48)
NEC	0/88 (0)	0/78 (0)	Cannot be estimated	Cannot be estimated
Esophageal probe issue	0/88 (0)	0/78 (0)	Cannot be estimated	Cannot be estimated
ECMO	0/88 (0)	0/78 (0)	Cannot be estimated	Cannot be estimated
Altered skin integrity				
Erythema	4/88 (4)	1/78 (1)	25	1.38 (0.53-3.73)
Sclerema	0/88 (0)	0/78 (0)	Cannot be estimated	Cannot be estimated
Cyanosis	1/88 (1)	0/78 (0)	Cannot be estimated	Cannot be estimated
Subcutaneous fat necrosis	0/88 (0)	0/78 (0)	Cannot be estimated	Cannot be estimated
For entire hospitalization				
Late-onset sepsis ^e	1/88 (1)	1/78 (1)	55	0.94 (0.32-2.71)
Oxygen, median (IQR), d	4 (0-29)	2 (0-87)	55	0.98 (0.70-1.37)
Mechanical ventilation, median (IQR), d	3.5 (0-64)	2 (0-57)	1	1.43 (1.08-1.90)
Length of hospital stay in survivors, median (IQR), d	22 (7-73)	22.5 (6-115)	32	1.04 (0.87-1.24)
No.	67	60	NA	NA

Abbreviations: aRR, adjusted relative risk; CrI, credibility interval; ECMO, extracorporeal membrane oxygenation; NA, not applicable; NEC, necrotizing enterocolitis; PPHN, pulmonary hypertension.

SI conversion factor: To convert calcium to millimoles per liter, divide by 10 and multiply by 0.25; potassium and sodium to millimoles per liter, multiply by 1.

^a Blood pH less than 2 SD and base deficit greater than 2 SD from time-specific values developing more than 3 hours after beginning of intervention period and persisting more than 3 hours.

^b Includes intraventricular, parenchymal, and cerebellar hemorrhage found on cranial ultrasound during or after intervention period, because cannot exclude possibility that hemorrhage detected after intervention actually occurred during the intervention.

^c Oliguria less than 0.5 mL/kg/h.

^d Liver dysfunction any of aspartate aminotransferase level greater than 200 IU/L, alanine aminotransferase level greater than 100 IU/L, or direct bilirubin level greater than 1.5 mg/dL.

^e Positive blood culture at greater than 3 days of age.

pragmatic randomized clinical trial conducted prospectively in 19 centers, well-defined inclusion and exclusion criteria, certified examiners to determine degree of encephalopathy at randomization, standardized interventions including steps to avoid confounding hyperthermia in the normothermic arm, systematic follow-up by certified examiners blinded to treatment assignment, and use of intention-to-treat design. Limitations include moderate sample size, inability to assign primary outcome to 11% of normothermic and 6% of hypothermic infants, loss to follow-up of more patients in the normothermic than hypothermic group, an intervention that was unblinded to clinicians (although

follow-up investigators were unaware of treatment assignment), and the fact that 47 infants were excluded from the study by clinicians opting for hypothermia without randomization (mean [SD] GA, 34.8 [0.6] weeks).

Conclusions

This randomized clinical trial provided evidence for no benefit from hypothermia in infants 33 to 35 weeks' GA with moderate or severe hypoxic-ischemic encephalopathy. Indeed, our findings suggest that it may increase death or

impairment. In the absence of strong supportive evidence from future trials, use of hypothermia is not indicated in infants born with hypoxic-ischemic encephalopathy at 35 weeks' GA or younger.

ARTICLE INFORMATION

Accepted for Publication: October 30, 2024.

Published Online: February 24, 2025.

doi:10.1001/jamapediatrics.2024.6613

Author Affiliations: Division of Neonatology, Department of Pediatrics, University of Utah Health Sciences Center, University of Utah, Salt Lake City, Utah (Faix, Yoder, Ohls, Winter); Women and Infants Hospital of Rhode Island, Brown University, Providence, Rhode Island (Laptook); Children's Hospital of Michigan and Hutzel Women's Hospital, Wayne State University, Detroit (Shankaran, Natarajan); Social, Statistical and Environmental Sciences Unit, RTI International, Research Triangle Park, North Carolina (Eggleston, Chowdhury); Parkland Memorial Hospital, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas (Heyne, Vasil, Chalak); Social, Statistical and Environmental Sciences Unit, RTI International, Rockville, Maryland (Das); Institute for Clinical Research and Learning Health Care, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston (Pedroza, Tyson, Mosquera); Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston (Pedroza, Mosquera); Lucille Salter Packard Children's Hospital at Stanford, Stanford University, Stanford, California (Wusthoff, Bonifacio, Van Meurs, Hintz); Current affiliation: University of California, Davis, Davis (Wusthoff); Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus (Sánchez, Bapat, Maitre, Benninger); University of North Carolina at Chapel Hill, Chapel Hill (Laughon, Trembath); Research and Sponsored Programs, Florida Gulf Coast University, Fort Myers (Crawford, Higgins); Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland (Higgins, Walsh); Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio (Poindexter, Merhar); Grady Memorial Hospital, Emory University Hospital Midtown, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia (Poindexter, Hamrick, Sewell, Maitre); University of Iowa, Iowa City (Colaizy, Harmon); University of Buffalo, Buffalo, New York (Hartley-McAndrew); Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia (Dysart, DeMauro, Duncan); University of Rochester, Rochester, New York (D'Angio, Guillet); WakeMed Health & Hospitals, Raleigh, North Carolina (Kicklighter); University of Alabama University Hospital, Birmingham (Carlo, Peralta-Carcelen); Riley Hospital for Children, Indiana University, Indianapolis (Sokol, Hines); Rainbow Babies and Children's Hospital, Case Western Reserve University, Cleveland, Ohio (Hibbs, Wilson-Costello); Duke University Hospital, Durham, North Carolina (Cotten, Malcolm).

Author Contributions: Dr Faix had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Faix, Laptook, Shankaran, Das, Pedroza, Tyson, Sanchez, Laughon, Higgins, Poindexter, Chalak, Hibbs, Duncan, Wilson-Costello, Walsh.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Faix, Shankaran, Eggleston, Chowdhury, Pedroza, Bonifacio, Sanchez, Vasil, Chalak, Dysart, D'Angio, Peralta-Carcelen.

Critical review of the manuscript for important intellectual content: Faix, Laptook, Shankaran, Eggleston, Chowdhury, Heyne, Das, Pedroza, Tyson, Wusthoff, Bonifacio, Sanchez, Yoder, Laughon, Van Meurs, Crawford, Higgins, Poindexter, Colaizy, Hamrick, Ohls, Hartley-McAndrew, Dysart, D'Angio, Guillet, Kicklighter, Carlo, Sokol, DeMauro, Hibbs, Cotten, Merhar, Bapat, Harmon, Sewell, Winter, Natarajan, Mosquera, Hintz, Maitre, Benninger, Hines, Duncan, Wilson-Costello, Trembath, Malcolm, Walsh.

Statistical analysis: Faix, Shankaran, Eggleston, Chowdhury, Das, Pedroza, Bonifacio.

Obtained funding: Faix, Shankaran, Das, Sanchez, Poindexter, Ohls, D'Angio, Hibbs, Merhar.

Administrative, technical, or material support: Faix, Shankaran, Tyson, Wusthoff, Bonifacio, Yoder, Vasil, Crawford, Higgins, Poindexter, Hamrick, D'Angio, Kicklighter, Carlo, Sokol, Hibbs, Bapat, Hintz, Maitre, Benninger, Duncan, Malcolm, Walsh.

Supervision: Faix, Shankaran, Das, Sanchez, Yoder, Van Meurs, Higgins, Poindexter, Chalak, Dysart, D'Angio, Carlo, Hibbs, Cotten, Merhar, Mosquera, Benninger, Peralta-Carcelen, Duncan, Wilson-Costello, Trembath, Walsh.

Conflict of Interest Disclosures: Dr Faix reported receiving grants from the National Institute of Child Health and Human Development (NICHD) and the National Center for Advancing Translational Sciences during the conduct of the study. Dr Laptook reported receiving grants from NICHD Neonatal Research Network during the conduct of the study. Dr Heyne reported receiving grants from NICHD during the conduct of the study and being a member of the board of directors of the nonprofit 501c3 Low Birth Weight Development Center and a member of the board of directors, regional director, and committee co-chair of the education committee of Catholic Medical Association and local Catholic Medical Guild. Dr Das reported receiving grants from NICHD and National Institutes of Health (NIH) during the conduct of the study. Dr Pedroza reported receiving grants from NICHD during the conduct of the study and funding from the National Heart, Lung, and Blood Institute and Department of Defense. Dr Sanchez reported receiving grants from NIH NICHD Neonatal Research Network during the conduct of the study. Dr Yoder reported receiving grants from NICHD during the conduct of the study. Dr Laughon reported receiving grants from NIH and US Food and Drug Administration outside the submitted work. Dr Vasil reported receiving grants from University of Texas Southwestern Medical Center during the conduct of the study. Dr Van Meurs reported receiving grants from NICHD during the conduct of the study. Dr Crawford reported receiving grants from NIH/HLBI during the conduct of the study. Dr Ohls reported receiving grants from NIH during the conduct of the study. Dr D'Angio reported receiving grants from NICHD during the conduct of the study. Dr Guillet reported receiving grants from NICHD and Hikma Pharmaceuticals and

being an investor in Zoro-Flow outside the submitted work. Dr Sokol reported receiving grants from NICHD during the conduct of the study. Dr DeMauro reported receiving grants from NIH during the conduct of the study. Dr Hibbs reported receiving grants from NIH during the conduct of the study. Dr Cotten reported receiving grants from NICHD, consulting fees from ReAlta Life Sciences, and royalties for a patent for CryoCell. Dr Sewell reported receiving grants from NICHD Cooperative Multicenter Neonatal Research Network during the conduct of the study. Dr Natarajan reported receiving grants from NICHD Neonatal Research Network during the conduct of the study. Dr Mosquera reported receiving grants from NICHD during the conduct of the study. Dr Hintz reported receiving grants from NICHD Neonatal Research Network during the conduct of the study. Dr Maitre reported being cofounder of and receiving equity from Thrive Neuromedical outside the submitted work. Dr Benninger reported receiving grants from NICHD, US Centers for Disease Control and Prevention MAT-LINK study, Patient-Centered Outcomes Research Institute COOL-PRIME study, and grants from National Institute of Neurological Disorders and Stroke (NINDS) HEAL trial outside the submitted work. Dr Peralta-Carcelen reported receiving grants from NIH during the conduct of the study. Dr Duncan reported receiving grants from NICHD during the conduct of the study. No other disclosures were reported.

Funding/Support: This study was supported in part by grants U10 HD27871, U10 HD53119, UG1 HD21364, UG1 HD21373, UG1 HD21385, UG1 HD27851, UG1 HD27853, UG1 HD27856, UG1 HD27880, UG1 HD27904, UG1 HD34216, UG1 HD36790, UG1 HD40492, UG1 HD40689, UG1 HD53089, UG1 HD53109, UG1 HD68244, UG1 HD68270, UG1 HD68278, UG1 HD68263, UG1 HD68284, UG1 HD87226, UG1 HD87229 from the National Institutes of Health and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and grants (UL1 TR6, UL1 TR41, UL1 TR42, UL1 TR77, UL1 TR93, UL1 TR442, UL1 TR454, UL1 TR1117) from the National Center for Advancing Translational Sciences (NCATS), which provided grant support through cooperative agreements for the Neonatal Research Network. The National Institutes of Health, the NICHD, the National Center for Research Resources, and the National Center for Advancing Translational Sciences provided grant support for the Neonatal Research Network's Preemie Hypothermia trial through cooperative agreements.

Role of the Funder/Sponsor: National Institute of Child Health and Human Development staff provided input into the study design, conduct, analysis, and manuscript drafting, but the funders had no role in the management and interpretation of the data; the preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Group Information: The members of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network are listed in [Supplement 4](#).

Disclaimer: Although the National Institute of Child Health and Human Development (NICHD) staff had

input into the study design, conduct, analysis, and manuscript drafting, the comments and views of the authors do not necessarily represent the views of NICHD, the National Institutes of Health, the Department of Health and Human Services, or the US government.

Data Sharing Statement: See [Supplement 5](#).

Additional Contributions: Participating Neonatal Research Network sites collected data and transmitted it to RTI International, the data coordinating center (DCC) for the network, which stored, managed and analyzed the data for this study. We are indebted to our medical and nursing colleagues and the infants and their parents who agreed to take part in this study. The following investigators, in addition to those listed as authors, participated in this study: NRN Steering Committee Chair: Richard A. Polin, MD, Division of Neonatology, College of Physicians and Surgeons, Columbia University, (2011-2023). Alpert Medical School of Brown University and Women & Infants Hospital of Rhode Island (UG1 HD27904)—Martin Keszler, MD; Nick Guerina, MD PhD; Adam Czynski, DO; Angelita M. Hensman, PhD RNC-NIC; Elisa Vieira, BSN RN; Lucille St. Pierre, BS; Barbara Alksninis, RNC PNP; Andrea Knoll; Mary L. Keszler, MD; Teresa M. Leach, MEd CAES; Elisabeth C. McGowan, MD; Victoria E. Watson, MS CAS. Case Western Reserve University, Rainbow Babies & Children's Hospital (UG1 HD21364)—Nancy S. Newman, RN; Bonnie S. Siner, RN; Harriet G. Friedman, MA. Cincinnati Children's Hospital Medical Center, University Hospital, and Good Samaritan Hospital (UG1 HD27853, UL1 TR77)—Kurt Schibler, MD; Tanya E. Cahill, MD; Cathy Grisby, BSN CCRC; Kristin Kirker, CRC; Sandra Wuertz, RN BSN CLC; Juanita Dudley, RN BSN; Julia Thompson, RN BSN; Lisa Henkes, RN BSN; Sara Stacey, BA; Devan Hayes, BS. Duke University School of Medicine, University Hospital, University of North Carolina, Duke Regional Hospital, and WakeMed Health & Hospitals (UG1 HD40492, UL1 TR1117)—Ronald N. Goldberg, MD; Patricia L. Ashley, MD; Deesha Mago-Shah, MD; Mollie Warren, MD; Joanne Probst, RN JD; Kimberley A. Fisher, PhD FNP-BC IBCLC; Kathryn E. Gustafson, PhD; Carl L. Bose, MD; Janice Bernhardt, MS RN; Gennie Bose, RN; Janice Wereszczak, CPNP-AC/PC; Jennifer Talbert, MS RN; Ryan Moore, MD; Alexandra Bentley, MD; Laura Edwards, MD; Ginger Rhodes-Ryan, ARNP MSN, NNP-BC; Donna White, RN-BC BSN. Emory University, Children's Healthcare of Atlanta, Grady Memorial Hospital, and Emory University Hospital Midtown (UG1 HD27851, UL1 TR454)—Ravi M. Patel, MD MSc; David P. Carlton, MD; Nathalie L. Maitre, MD PhD; Ira Adams-Chapman, MD (deceased); Yvonne Loggins, RN; Diane Bottcher, RN; Sheena L. Carter, PhD; Salathiel Kendrick-Allwood, MD; Maureen Mulligan LaRossa, RN; Judith Laursen, RN; Colleen Mackie, RRT; Amy Sanders, PsyD; Gloria Smikle, PNP; Lynn Wineski, NNP. Eunice Kennedy Shriver National Institute of Child Health and Human Development—Andrew A. Bremer, MD PhD. Indiana University, University Hospital, Methodist Hospital, Riley Hospital for Children, and Wishard Health Services (UG1 HD27856, UL1 TR6)—Lu Ann Papile, MD; Dianne E. Herron, RN CCRC; Carolyn Lytle, MD MPH; Lucy Smiley, CCRC; Leslie Dawn Wilson, BSN CCRC; Donna Watkins, MSN NNP-BC; Susan Gunn, NNP-BC CCRC; Jeff Joyce, CCRC (deceased). McGovern Medical School at The University of Texas Health Science Center at Houston, Children's

Memorial Hermann Hospital, and Memorial Hermann Southwest Hospital (U10 HD21373, UG1 HD87229)—Amir M. Khan, MD; Kathleen A. Kennedy, MD MPH; Barbara J. Stoll, MD; Elizabeth Allain, PhD; Julie Arldt-McAlister, MSN APRN; Fatima Boricha, MD; Allison G. Dempsey, PhD; Carmen Garcia, RN BSN; Donna J. Hall, RN; Janice John, CPNP; M. Layne Lillie, RN BSN; Karen Martin, RN; Georgia E. McDavid, RN; Shannon L. McKee, EdS; Michelle Poe, PhD RN; Kimberly Rennie, PhD; Tina Reddy, MD; Shawna Rodgers, RNC-NIC BSN; Daniel K. Sperry, RN; Emily Stephens, BSN RNC-NIC; Sharon L. Wright, MT (ASCP). Nationwide Children's Hospital, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Center for Perinatal Research, The Ohio State University College of Medicine, The Ohio State University Wexner Medical Center, and Riverside Methodist Hospital (UG1 HD68278)—Leif D. Nelin, MD; Jonathan L. Slaughter, MD MPH; Sudarshan R. Jachlerla, MD; Christopher Timan, MD; Patricia Luzader, RN; Julie Gutentag, RN BSN; Jennifer L. Grothouse, BA RN BSN; Melanie Stein, RRT BBS; Rox Ann Sullivan, RN BSN; Helen Carey, PT DHSc PCS; Stephanie Burkhardt, BS MPH; Mary Ann Nelin, MD; Erna Clark, BA; Julie C. Shadd, BSN RD; Courtney Park, RN BSN; Kristi Small, BS; Jacqueline McCool; Lindsay Pietruszewski, PT DPT; Jessica Purnell, BS CCRC; Kyrstin Warnimont, BS; Laura Marzec, MD; Bethany Miller, RN BSN; Demi R. Beckford, MHS; Hallie Baugher, BS MSN; Julia Newton, MPH; Katelyn Levensgood, PT DPT; Nancy Batterson, OT/L; Brittany DeSantis, BS; Jessica Schiering, BSN CCRC RN; Kelly Schmidt, BA Med PhD; Eduardo Finol Mark, MD; Jordan Knox, BS; Abbie M. Tice, MOT OTR/L; Laurel A. Slaughter, MD; Chelsea Cobe, BA. RTI International (UG1 HD36790)—Carla M. Bann, PhD; Dennis Wallace, PhD; Marie G. Gantz, PhD; Jeanette O'Donnell Auman, BS; Jenna Gabrio, BS MPH; Jamie E. Newman, PhD MPH; Lindsay Parlborg, BS; Carolyn M. Petrie Huitema, MS; Kristin M. Zaterka-Baxter, RN BSN. Stanford University, El Camino Hospital, and Lucile Packard Children's Hospital (UG1 HD27880, UL1 TR93)—David K. Stevenson, MD; M. Bethany Ball, BS CCRC; Valerie Y. Chock, MD MS Epi; Marian M. Adams, MD; Alexis S. Davis, MD MS Epi; Meera N. Sankar, MD; Dharshi Sivakumar, MD; Lilia Rutkowska, MA; Dona Bahmani, CRC; Barbara Bentley, PsychD MScEd; Maria Elena DeAnda, PhD; Anne M. DeBattista, RN PNP PhD; Beth Earhart, PhD; Lynne C. Huffman, MD; Casey E. Krueger, PhD; Ryan E. Lucash, PhD; Melinda S. Proud, RCP; Elizabeth N. Reichert, MA CCRC; Heather Taylor, PhD; Hali E. Weiss, MD; R. Jordan Williams, MD. University of Alabama at Birmingham Health System and Children's Hospital of Alabama (UG1 HD34216)—Namasivayam Ambalavanan, MD; Kirstin J. Bailey, PhD; Fred J. Biasini, PhD; Stephanie A. Chopko, PhD; Monica V. Collins, RN BSN MA; Shirley S. Cosby, RN BSN; Kristy A. Domnanovich, PhD; Chantel J. Jno-Finn, PT DPT; Morissa Ladinsky, MD; Mary Beth Moses, PT MS PCS; Tara E. McNair, RN BSN; Vivien A. Phillips, RN BSN; Julie Preskitt, MSOT MPH; Richard V. Rector, PhD; Kimberly Stringer, MD MPH; Sally Whitley, MA OTR-L FAOTA; Sheree York Chapman, PT DPT PCS. University of Iowa, Mercy Medical Center, and Sanford Health (UG1 HD53109, UL1 TR442)—Edward F. Bell, MD; Jane E. Brumbaugh, MD; Michelle L. Baack, MD; Karen J. Johnson, RN BSN; Mendi L. Schmelzel, RN MSN; Jacky R. Walker, RN; Claire A. Goeke, RN; Diane L. Eastman, RN CPNP MA; Laurie A. Hogden, MD; Megan M.

Henning, RN; Chelsey Elenkiwich, BSN RN; Megan Broadbent, RN BSN; Sarah Van Muyden, RN BSN; Dan L. Ellsbury, MD; Tracy L. Tud, RN. University of Pennsylvania, Hospital of the University of Pennsylvania, Pennsylvania Hospital, Children's Hospital of Philadelphia, and Virtua Voorhees Hospital (UG1 HD68244)—Eric C. Eichenwald, MD; Sara C. Handley, MD MSCE; Barbara Schmidt, MD MSc; Hareesh Kirpalani, MB MSc; John Flibotte, MD; Karen M. Puopolo, MD PhD; Soraya Abbasi, MD; Elizabeth E. Foglia, MD MSCE; Aasma S. Chaudhary, BS RRT; Toni Mancini, RN BSN CCRC; Dara M. Cucinotta, RN; Judy C. Bernbaum, MD; Marsha Gerdes, PhD; Sarvin Ghavam, MD; Hallam Hurt, MD; Jonathan Snyder, RN BSN, Kristina Ziolkowski, CMA(AAMA) CCRP. University of Rochester Medical Center, Golisano Children's Hospital, and the University of Buffalo Women's and Children's Hospital of Buffalo (UG1 HD68263, UL1 TR42)—Ronnie Guillet, MD PhD; Satyan Lakshminrusimha, MD; Gary J. Myers, MD; Holly I.M. Wadkins; Michael G. Sacilowski, BS; Rosemary L. Jensen; Joan Merzbach, LMSW; William Zorn, PhD; Osman Farooq, MD; Stephanie Guilford, BS; Kelley Yost, PhD; Mary Rowan, RN; Diane Prinzing; Ann Marie Scorsone, MS CCRC; Kyle Binion, BS; Constance Orme; Premini Sabaratnam, MPH; Alison Kent, BMBS FRACP MD; Rachel Jones; Elizabeth Boylin, BA; Daisy Rochez, BS MHA; Emily Li, BA; Jennifer Kachelmeyer, BS; Kimberly G. McKee, BS; Kelly R. Coleman, PsyD; Deanna Maffett, RN. University of Texas Southwestern Medical Center, Parkland Health & Hospital System, and Children's Medical Center Dallas (UG1 HD40689)—Luc P. Brion, MD; Maria M. De Leon, RN BSN; Frances Eubanks, RN BSN; E. Rebecca McDougald, MSN APRN CPNP-PC/AC; Lara Pavageau, MD; Pollianna Sepulveda, RN; Alicia Guzman; Elizabeth Heyne, PsyD PA-C; Lizette E. Lee, RN; Azucena Vera, AS; Jillian Waterbury, DNP RN CPNP-PC; Cathy Twell Boatman, MS CIMI; Kristine Tolentino-Plata, MS. University of Utah Medical Center, Intermountain Medical Center, McKay-Dee Hospital, Utah Valley Hospital, and Primary Children's Medical Center (UG1 HD87226, UL1 TR105)—Mariana Baserga, MD MSCI; Stephen D. Minton, MD; Mark J. Sheffield, MD; Carrie A. Rau, RN BSN CCRC; Shawna Baker, RN; Jill Burnett, RNC BSN; Susan Christensen, RN; Sean D. Cunningham, PhD; Brandy Davis, RN BSN; Jennifer O. Elmont, RN BSN; Becky Hall, APRN; Erika R. Jensen, APRN; Jamie Jordan, RN BSN; Manndi C. Loertscher, BS CCRP; Trisha Marchant, RNC BSN; Eric Maxson, RN CCRN; Kandace M. McGrath, BS; Hena G. Mickelsen, BA; Galina Morshedzadeh, BSN APRN; D. Melody Parry, RN BSN; Susan T. Schaefer, RN BSN RRT; Kelly Stout, PhD; Ashley L. Stuart, PhD; Katherine Tice, RN BSN; Kimberlee Weaver-Lewis, RN MS; Kathryn D. Woodbury, RN BSN. Wayne State University, Hutzel Women's Hospital, and Children's Hospital of Michigan (UG1 HD21385) and Univ. Michigan Ann Arbor —Beena G. Sood, MD MS; Athina Pappas, MD; Sanjay Chawla, MD; Monika Bajaj, MD; Prashant Agarwal, MD; Jeanette Prentice, MD; Melissa February, MD; Lilia De Jesus, MD; Gerry Muran, RN; Rebecca Bara, RN BSN; Kirsten Childs, RN BSN; Bogdan Panaitescu, MD; Eunice Woldt, RN MSN; Mary E. Johnson, RN BSN; Laura A. Goldston, MA; Stephanie A. Wiggins, MS; Mary K. Christensen, BA RRT; Diane F. White, RN MSN; Martha Carlson, MD; John Barks, MD. Beyond usual salary, no one received financial compensation for their contributions.

REFERENCES

- Gluckman PD, Wyatt JS, Azzopardi D, et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicenter randomized trial. *Lancet*. 2005;365(9460):663-670. doi:10.1016/S0140-6736(05)17946-X
- Shankaran S, Laptook AR, Ehrenkranz RA, et al; National Institute of Child Health and Human Development Neonatal Research Network. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. *N Engl J Med*. 2005;353(15):1574-1584. doi:10.1056/NEJMcps050929
- Azzopardi DV, Strohm B, Edwards AD, et al; TOBY Study Group. Moderate hypothermia to treat perinatal asphyxial encephalopathy. *N Engl J Med*. 2009;361(14):1349-1358. doi:10.1056/NEJMoA0900854
- Zhou WH, Cheng GQ, Shao XM, et al; China Study Group. Selective head cooling with mild systemic hypothermia after neonatal hypoxic-ischemic encephalopathy: a multicenter randomized controlled trial in China. *J Pediatr*. 2010;157(3):367-372. doi:10.1016/j.jpeds.2010.03.030
- Simbruner G, Mittal RA, Rohlmann F, Muche R; neo.nEURO.network Trial Participants. Systemic hypothermia after neonatal encephalopathy: outcomes of neo.nEURO.network RCT. *Pediatrics*. 2010;126(4):e771-e778. doi:10.1542/peds.2009-2441
- Shipley L, Gale C, Sharkey D. Trends in the incidence and management of hypoxic-ischemic encephalopathy in the therapeutic hypothermia era: a national population study. *Arch Dis Child Fetal Neonatal Ed*. 2021;106(5):529-534. doi:10.1136/archdischild-2020-320902
- Berg M. Therapeutic hypothermia increased 66% from 2012 to 2021. Accessed March 30, 2023. <https://public.vtoxford.org/nicu-by-the-numbers/therapeutic-hypothermia-increased-66-from-2012-to-2021>.
- Rao R, Trivedi S, Vesoulis Z, Liao SM, Smyser CD, Mathur AM. Safety and short-term outcomes of therapeutic hypothermia in preterm neonates 34-35 weeks gestational age with hypoxic-ischemic encephalopathy. *J Pediatr*. 2017;183:37-42. doi:10.1016/j.jpeds.2016.11.019
- Herrera TI, Edwards L, Malcolm WF, et al. Outcomes of preterm infants treated with hypothermia for hypoxic-ischemic encephalopathy. *Early Hum Dev*. 2018;125:1-7. doi:10.1016/j.earlhumdev.2018.08.003
- Moran P, Sullivan K, Zanelli SA, Burnes J. Single-center experience with therapeutic hypothermia for hypoxic-ischemic encephalopathy in infants with <36 weeks' gestation. *Am J Perinatol*. 2024;41(12):1680-1687. doi:10.1055/a-2251-6317
- Kim SH, El-Shibiny H, Inder T, El-Dib M. Therapeutic hypothermia for preterm infants 34-35 weeks gestational age with neonatal encephalopathy. *J Perinatol*. 2024;44(4):528-531. doi:10.1038/s41372-024-01874-x
- Laptook AR, Shankaran S, Tyson JE, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Effect of therapeutic hypothermia initiated after 6 hours of age on death or disability among newborns with hypoxic-ischemic encephalopathy: a randomized clinical trial. *JAMA*. 2017;318(16):1550-1560. doi:10.1001/jama.2017.14972
- Shankaran S, Laptook AR, Pappas A, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Effect of depth and duration of cooling on death or disability at age 18 months among neonates with hypoxic-ischemic encephalopathy: a randomized clinical trial. *JAMA*. 2017;318(1):57-67. doi:10.1001/jama.2017.7218
- Volpe JJ. *Neurology of the Newborn*. 5th ed. Saunders Elsevier; 2008:121-153.
- Wyatt JS, Gluckman PD, Liu PY, et al; CoolCap Study Group. Determinants of outcomes after head cooling for neonatal encephalopathy. *Pediatrics*. 2007;119(5):912-921. doi:10.1542/peds.2006-2839
- Laptook A, Tyson J, Shankaran S, et al; National Institute of Child Health and Human Development Neonatal Research Network. Elevated temperature after hypoxic-ischemic encephalopathy: risk factor for adverse outcomes. *Pediatrics*. 2008;122(3):491-499. doi:10.1542/peds.2007-1673
- Laptook AR, McDonald SA, Shankaran S, et al; Extended Hypothermia Follow-up Subcommittee of the National Institute of Child Health and Human Development Neonatal Research Network. Elevated temperature and 6- to 7-year outcome of neonatal encephalopathy. *Ann Neurol*. 2013;73(4):520-528. doi:10.1002/ana.23843
- Bell MJ, Ternberg JL, Feigin RD, et al. Neonatal necrotizing enterocolitis—therapeutic decisions based upon clinical staging. *Ann Surg*. 1978;187(1):1-7. doi:10.1097/0000658-197801000-00001
- Lilford RJ, Thornton JG, Brauholtz D. Clinical trials and rare diseases: a way out of a conundrum. *BMJ*. 1995;311(7020):1621-1625. doi:10.1136/bmj.311.7020.1621
- Wijeyesundera DN, Austin PC, Hux JE, Beattie WS, Laupacis A. Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials. *J Clin Epidemiol*. 2009;62(1):13-21.e5. doi:10.1016/j.jclinepi.2008.07.006
- Gelman A, Pardoe I. Average predictive comparisons for models with nonlinearity, interactions and variance components. *Sociol Methodol*. 2007;37(1):23-51. doi:10.1111/j.1467-9531.2007.00181.x
- Pedroza C, Han W, Truong VTT, Green C, Tyson JE. Performance of informative priors skeptical of large treatment effects in clinical trials: a simulation study. *Stat Methods Med Res*. 2018;27(1):79-96. doi:10.1177/0962280215620828
- Jacobs SE, Morley CJ, Inder TE, et al; Infant Cooling Evaluation Collaboration. Whole-body hypothermia for term and near-term newborns with hypoxic-ischemic encephalopathy: a randomized controlled trial. *Arch Pediatr Adolesc Med*. 2011;165(8):692-700. doi:10.1001/archpediatrics.2011.43
- Eicher DJ, Wagner CL, Katikaneni LP, et al. Moderate hypothermia in neonatal encephalopathy: efficacy outcomes. *Pediatr Neurol*. 2005;32(1):11-17. doi:10.1016/j.pediatrneurol.2004.06.014
- Eicher DJ, Wagner CL, Katikaneni LP, et al. Moderate hypothermia in neonatal encephalopathy: safety outcomes. *Pediatr Neurol*. 2005;32(1):18-24. doi:10.1016/j.pediatrneurol.2004.06.015
- Papile LA, Baley JE, Benitz W, et al; Committee on Fetus and Newborn. Hypothermia and neonatal encephalopathy. *Pediatrics*. 2014;133(6):1146-1150. doi:10.1542/peds.2014-0899
- Chalak LF, Rollins N, Morris MC, Brion LP, Heyne R, Sánchez PJ. Perinatal acidosis and hypoxic-ischemic encephalopathy in preterm infants of 33 to 35 weeks' gestation. *J Pediatr*. 2012;160(3):388-394. doi:10.1016/j.jpeds.2011.09.001